PLRX (Pliant Therapeutics) Other Current Liabilities: $2.29 Mil (As of Mar. 2026)


PLRX Pliant Therapeutics Inc PLRX
31 GF Score
Price $1.17
! 2 Warning Signs
View Full Analysis

What is Pliant Therapeutics Other Current Liabilities?

Pliant Therapeutics PLRX +5.41% 31 Other Current Liabilities is $2.29 Mil as of Mar. 2026. GuruFocus rates PLRX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Pliant Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $2.29 Mil.

Pliant Therapeutics's quarterly other current liabilities increased from Sep. 2025 ($6.95 Mil) to Dec. 2025 ($8.30 Mil) but then declined from Dec. 2025 ($8.30 Mil) to Mar. 2026 ($2.29 Mil).

Pliant Therapeutics's annual other current liabilities increased from Dec. 2023 ($9.04 Mil) to Dec. 2024 ($11.15 Mil) but then declined from Dec. 2024 ($11.15 Mil) to Dec. 2025 ($8.30 Mil).

Pliant Therapeutics Other Current Liabilities Related Terms

Pliant Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pliant Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pliant Therapeutics Other Current Liabilities Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 5.22 7.20 9.04 11.15 8.30

Pliant Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.39 6.23 6.95 8.30 2.29
PLRX
31GF Score
Pliant Therapeutics Inc PLRX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pliant Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $2.29 Mil mean?
Pliant Therapeutics (PLRX) has a Other Current Liabilities of $2.29 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pliant Therapeutics.
Is Pliant Therapeutics' Other Current Liabilities too high?
Pliant Therapeutics' current Other Current Liabilities is $2.29 Mil. Overall, Pliant Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pliant Therapeutics' Other Current Liabilities compare to BYSI and MCRB?
Pliant Therapeutics' Other Current Liabilities of $2.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pliant Therapeutics. Pliant Therapeutics's current Other Current Liabilities is $2.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pliant Therapeutics stock overvalued right now?
Pliant Therapeutics (PLRX) has a current Other Current Liabilities of $2.29 Mil. The current Other Current Liabilities is $2.29 Mil. Pliant Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Pliant Therapeutics (PLRX), the current Other Current Liabilities is $2.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pliant Therapeutics Business Description

Other Exchanges 9PT:Germany
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
31GF Score

Get the complete analysis for PLRX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.17
Price